Shionogi Company Limited

Kohji Hanasaki

Hideyuki Takenaka

Tetsuo Okada

Yukio Tada

Yasuyuki Kawanishi

Jun Ishizaki

Yasuyoshi Iso

Noriko Suzuki

Takashi Ono

Ryuji Suzuki

Saichi Matsumoto

Tsuneaki Sakata

Hirokuni Jyoyama

Kenzo Koizumi

Minoru Ikeda

Shinji Kakudo

Tomoyuki Ogawa

Kaoru Seno

The present invention provides a pharmaceutical composition for use as an NPY Y5 receptor antagonist comprising a compound or the formula (I): 

NPY Y5 antagonist

It was found that the compound having a binding activity to the cannabinoid type 2 receptor represented by the formula (I): wherein Ris a group represented by the formula: &#x2014;Y&#x2014;Y&#x2014;Y&#x2014;Rwherein Yis single bond or the like; Yis &#x2014;C(&#x2550;O)&#x2014;NH&#x2014; or the like; Yis optionally substituted aryl or the like; Ris hydrogen or the like; Ris alkyl or the like; Ris alkyl or the like; Ris optionally substituted alkyl or the like; or Rand Rtaken together with the adjacent atom form cyclic group or the like.

Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor

The present invention provides a pharmaceutical composition for use as an NPY Y5 receptor antagonist comprising a compound of the formula (I): wherein Ris lower alkyl, cycloalkyl or the like,

A compound represented by the general formula:wherein Ris &#x2014;CHCOOH and the like; Ris &#x2014;COCONHand the like; Ris C4&#x2013;C6 alkyl; and the like; Ris &#x2014;CH&#x2014;Rwherein Ris aryl and the like; Ris hydrogen or C1&#x2013;C6 alkyl and the like; an optical active compound, a prodrug thereof, or a pharmaceutically acceptable salt, or a solvate having type X sPLAinhibitory effect was found.

[object Object]

It was found that the compound having a binding activity to the cannabinoid type 2 receptor represented by the formula (I):&#x2003;wherein Ris a group represented by the formula: &#x2014;Y&#x2014;Y&#x2014;Y&#x2014;Rwherein Yis single bond or the like; Yis &#x2014;C(&#x2550;O)&#x2014;NH&#x2014; or the like; Yis optionally substituted aryl or the like; Ris hydrogen or the like; Ris alkyl or the like; Ris alkyl or the like; Ris optionally substituted alkyl or the like; or Rand Rtaken together with the adjacent atom form cyclic group or the like.

Pyridone derivatives having affinity for cannabinoid 2-type receptor

This invention relates to a gene encoding human secretory type phospholipase A(PLA). According to the invention, an expression vector having this gene, and a transformant having the expression vector are obtainable. The PLAprotein can be produced by the culture of the transformant.

Human secretory type phospholipase A2

It is provided that type-X sPLAinhibitors are useful in preventing or treating hepatocirrhosis.

Remedies for cirrhosis

Gene encoding novel human secretory phospholipase A2

This invention relates to a gene encoding human secretory type phospholipase A (PLA ). According to the invention, an expression vector having this gene, and a transformant having the expression vector are obtainable. The PLA protein can be produced by the culture of the transformant.

Growing community of inventors

Osaka, Japan

Kohji Hanasaki